MAPK1 and Parkinson disease: The study results suggest that miR-124 can inhibit neuroinflammation during PD development by targeting p62, p38, and autophagy, indicating that miR-124 could be a potential therapeutic target for regulating the inflammatory response in PD (Yao et al., 2019).